Home Newsfeeds Baird Maintains Neutral on Autoliv, Raises Price Target to $81

Baird Maintains Neutral on Autoliv, Raises Price Target to $81

Baird analyst Luke Junk maintains Autoliv (NYSE:ALV) with a Neutral and raises the price target from $77 to $81.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Baird analyst Luke Junk maintains Autoliv (NYSE:ALV) with a Neutral and raises the price target from $77 to $81.

$1000 Invested In Activision Blizzard 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

February 10, 4:31 PM

Activision Blizzard (NASDAQ:ATVI) has outperformed the market over the past 15 years by 4.67% on an annualized basis…

ATVI

HSBC Analyst Sees Nvidia Stock Climbing Another 50% On Strong Pricing Power, AI Roadmap

By Vaishali Prayag

May 13, 2:40 PM

HSBC Global Research maintained Nvidia Corp (NASDAQ:NVDA) with a Buy rating Monday and lifted its 12-month price target as the firm believes the chipmaker's strong pricing power will allow the company to continue to deliver upside surprises through fiscal-year 2026.

NVDA

News

Micron DDR5 Delivers Increased Performance And Reliability For The 4th Gen Intel Xeon Scalable Processor Family

By Benzinga Newsdesk

January 10, 2:03 PM

Micron Technology, Inc. (NASDAQ:MU), today announced that its DDR5 server memory portfolio for the data center is now fully validated on the 4th Gen Intel Xeon Scalable processor family. Micron

INTC

Analyst Ratings

Raymond James Maintains Outperform Rating for PTC Therapeutics: Here’s What You Need To Know

By Benzinga Insights

August 4, 1:00 PM

Raymond James has decided to maintain its Outperform rating of PTC Therapeutics (NASDAQ:PTCT) and lower its price target…

PTCT

Baird Maintains Neutral on Autoliv, Raises Price Target to $81

Related Posts

$1000 Invested In Activision Blizzard 15 Years Ago Would Be Worth This Much Today

HSBC Analyst Sees Nvidia Stock Climbing Another 50% On Strong Pricing Power, AI Roadmap

Micron DDR5 Delivers Increased Performance And Reliability For The 4th Gen Intel Xeon Scalable Processor Family

Raymond James Maintains Outperform Rating for PTC Therapeutics: Here’s What You Need To Know